|
1
|
Alshatwi AA, Hasan TN, Shafi G, Syed NA,
Al-Assaf AH, Alamri MS and Al-Khalifa AS: Validation of the
antiproliferative effects of organic extracts from the green husk
of Juglans regia L. on PC3 human prostate cancer cells by
assessment of apoptosis-related genes. Evid Based Complement
Alternat Med. 2012:Feb 6–2012.(Epub ahead of print).
|
|
2
|
Malek A, Núñez LE, Magistri M, et al:
Modulation of the activity of Sp transcription factors by
mithramycin analogues as a new strategy for treatment of metastatic
prostate cancer. PLoS One. 7:e351302012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Soriano-Hernández AD, Galvan-Salazar HR,
Montes-Galindo DA, et al: Antitumor effect of meclofenamic acid on
human androgen-independent prostate cancer: a preclinical
evaluation. Int Urol Nephrol. 44:471–477. 2012.PubMed/NCBI
|
|
4
|
Sankpal UT, Abdelrahim M, Connelly SF, et
al: Small molecule tolfenamic acid inhibits PC3 cell proliferation
and invasion in vitro, and tumor growth in orthotopic mouse model
for prostate cancer. Prostate. 72:1648–1658. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lou Z, O’Reilly S, Liang H, Maher VM,
Sleight SD and McCormick JJ: Down-regulation of overexpressed sp1
protein in human fibrosarcoma cell lines inhibits tumor formation.
Cancer Res. 65:1007–1017. 2005.PubMed/NCBI
|
|
6
|
Chintharlapalli S, Papineni S, Ramaiah SK
and Safe S: Betulinic acid inhibits prostate cancer growth through
inhibition of specificity protein transcription factors. Cancer
Res. 67:2816–2823. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Choi ES, Shim JH, Jung JY, et al:
Apoptotic effect of tolfenamic acid in androgen
receptor-independent prostate cancer cell and xenograft tumor
through specificity protein 1. Cancer Sci. 102:742–748. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shim JH, Shin JA, Jung JY, et al:
Chemopreventive effect of tolfenamic acid on KB human cervical
cancer cells and tumor xenograft by downregulating specificity
protein 1. Eur J Cancer Prev. 20:102–111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang CZ, Pan Y, Cao Y, Lai PB, Liu L,
Chen GG and Yun J: Histone deacetylase inhibitors facilitate
dihydroartemisinin-induced apoptosis in liver cancer in vitro and
in vivo. PLoS One. 7:e398702012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roh MS, Kim CW, Park BS, et al: Mechanism
of histone deacetylase inhibitor Trichostatin A induced apoptosis
in human osteosarcoma cells. Apoptosis. 9:583–589. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vallo S, Mani J, Stastny M, et al: The
prostate cancer blocking potential of the histone deacetylase
inhibitor LBH589 is not enhanced by the multi receptor tyrosine
kinase inhibitor TKI258. Invest New Drugs. 31:265–272. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rikiishi H: Autophagic and apoptotic
effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol.
2011:May 18–2011.(Epub ahead of print).
|
|
13
|
Perego P, Zuco V, Gatti L and Zunino F:
Sensitization of tumor cells by targeting histone deacetylases.
Biochem Pharmacol. 83:987–994. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Khan O and La Thangue NB: HDAC inhibitors
in cancer biology: emerging mechanisms and clinical applications.
Immunol Cell Biol. 90:85–94. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Marks PA: The clinical development of
histone deacetylase inhibitors as targeted anticancer drugs. Expert
Opin Investig Drugs. 19:1049–1066. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chou YW, Chaturvedi NK, Ouyang S, et al:
Histone deacetylase inhibitor valproic acid suppresses the growth
and increases the androgen responsiveness of prostate cancer cells.
Cancer Lett. 311:177–186. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hudak L, Tezeeh P, Wedel S, et al: Low
dosed interferon alpha augments the anti-tumor potential of histone
deacetylase inhibition on prostate cancer cell growth and invasion.
Prostate. 72:1719–1735. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim NH, Kim SN and Kim YK: Involvement of
HDAC1 in E-cadherin expression in prostate cancer cells; its
implication for cell motility and invasion. Biochem Biophys Res
Commun. 404:915–921. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gravina GL, Marampon F, Giusti I, et al:
Differential effects of PXD101 (belinostat) on androgen-dependent
and androgen-independent prostate cancer models. Int J Oncol.
40:711–720. 2012.PubMed/NCBI
|
|
20
|
Zhou X, Yang XY and Popescu NC:
Preclinical evaluation of combined antineoplastic effect of DLC1
tumor suppressor protein and suberoylanilide hydroxamic acid on
prostate cancer cells. Biochem Biophys Res Commun. 420:325–330.
2012. View Article : Google Scholar
|
|
21
|
Lai MT, Yang CC, Lin TY, Tsai FJ and Chen
WC: Depsipeptide (FK228) inhibits growth of human prostate cancer
cells. Urol Oncol. 26:182–189. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bjorkman M, Iljin K, Halonen P, Sara H,
Kaivanto E, Nees M and Kallioniemi OP: Defining the molecular
action of HDAC inhibitors and synergism with androgen deprivation
in ERG-positive prostate cancer. Int J Cancer. 123:2774–2781. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Abdelrahim M, Smith R 3rd, Burghardt R and
Safe S: Role of Sp proteins in regulation of vascular endothelial
growth factor expression and proliferation of pancreatic cancer
cells. Cancer Res. 64:6740–6749. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Abdelrahim M, Samudio I, Smith R 3rd,
Burghardt R and Safe S: Small inhibitory RNA duplexes for Sp1 mRNA
block basal and estrogen-induced gene expression and cell cycle
progression in MCF-7 breast cancer cells. J Biol Chem.
277:28815–28822. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Safe S and Abdelrahim M: Sp transcription
factor family and its role in cancer. Eur J Cancer. 41:2438–2448.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yao JC, Wang L, Wei D, et al: Association
between expression of transcription factor Sp1 and increased
vascular endothelial growth factor expression, advanced stage, and
poor survival in patients with resected gastric cancer. Clin Cancer
Res. 10:4109–4117. 2004. View Article : Google Scholar
|
|
27
|
Wang L, Wei D, Huang S, et al:
Transcription factor Sp1 expression is a significant predictor of
survival in human gastric cancer. Clin Cancer Res. 9:6371–6380.
2003.PubMed/NCBI
|
|
28
|
Zannetti A, Del Vecchio S, Carriero MV, et
al: Coordinate up-regulation of Sp1 DNA-binding activity and
urokinase receptor expression in breast carcinoma. Cancer Res.
60:1546–1551. 2000.PubMed/NCBI
|
|
29
|
Hosoi Y, Watanabe T, Nakagawa K, et al:
Up-regulation of DNA-dependent protein kinase activity and Sp1 in
colorectal cancer. Int J Oncol. 25:461–468. 2004.PubMed/NCBI
|
|
30
|
Ishibashi H, Nakagawa K, Onimaru M, et al:
Sp1 decoy transfected to carcinoma cells suppresses the expression
of vascular endothelial growth factor, transforming growth factor
beta1, and tissue factor and also cell growth and invasion
activities. Cancer Res. 60:6531–6536. 2000.
|
|
31
|
Chadalapaka G, Jutooru I, Chintharlapalli
S, Papineni S, Smith R 3rd, Li X and Safe S: Curcumin decreases
specificity protein expression in bladder cancer cells. Cancer Res.
68:5345–5354. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jutooru I, Chadalapaka G, Lei P and Safe
S: Inhibition of NFkappaB and pancreatic cancer cell and tumor
growth by curcumin is dependent on specificity protein
down-regulation. J Biol Chem. 285:25332–25344. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chu S and Ferro TJ: Sp1: regulation of
gene expression by phosphorylation. Gene. 348:1–11. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Deniaud E, Baguet J, Chalard R, et al:
Overexpression of transcription factor Sp1 leads to gene expression
perturbations and cell cycle inhibition. PLoS One. 4:e70352009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Choi KH, Shim JH, Huong LD, Cho NP and Cho
SD: Inhibition of myeloid cell leukemia-1 by tolfenamic acid
induces apoptosis in mucoepidermoid carcinoma. Oral Dis.
17:469–475. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yu DC, Waby JS, Chirakkal H, Staton CA and
Corfe BM: Butyrate suppresses expression of neuropilin I in
colorectal cell lines through inhibition of Sp1 transactivation.
Mol Cancer. 9:2762010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu J, Zhou JY, Wei WZ, Philipsen S and Wu
GS: Sp1-mediated TRAIL induction in chemosensitization. Cancer Res.
68:6718–6726. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kadonaga JT, Courey AJ, Ladika J and Tjian
R: Distinct regions of Sp1 modulate DNA binding and transcriptional
activation. Science. 242:1566–1570. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pietrzak M and Puzianowska-Kuznicka M:
p53-dependent repression of the human MCL-1 gene encoding an
anti-apoptotic member of the BCL-2 family: the role of Sp1 and of
basic transcription factor binding sites in the MCL-1 promoter.
Biol Chem. 389:383–393. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li F and Altieri DC: Transcriptional
analysis of human survivin gene expression. Biochem J. 344:305–311.
1999. View Article : Google Scholar
|
|
41
|
Li Y, Xie M, Yang J, Yang D, Deng R, Wan Y
and Yan B: The expression of antiapoptotic protein survivin is
transcriptionally upregulated by DEC1 primarily through multiple
sp1 binding sites in the proximal promoter. Oncogene. 25:3296–3306.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wu J, Ling X, Pan D, et al: Molecular
mechanism of inhibition of survivin transcription by the GC-rich
sequence-selective DNA binding antitumor agent, hedamycin: evidence
of survivin down-regulation associated with drug sensitivity. J
Biol Chem. 280:9745–9751. 2005. View Article : Google Scholar
|
